Tenghui Chen United States

Cancer Immunotherapy development
Partnering Objectives
Headquartner in China
Biotech/Pharma Category
PepGene Inc
CTO 

ming chen China

haitong
Website:
www.haitong.com
Partnering Objectives
Headquartner in China
haitong security
analyst 

Miss Ocean Chen China

Currently, TopWin Pharma. has developed to a high-tech group involving the biological and chemical medicine. TopWin Pharmaceutical Group's business has covered all aspects of R&D of new drugs, including clinical research, registration, production and sale. With the mission of "bringing benefits to mankind through innovation and technology", Topwin Group has been cooperating with well-known domestic and international drug R&D institutions to build TopWin Pharma. into a leading domestic and world-class pharmaceutical enterprise.
Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
Oncology domain, clinical phase innovative project
Headquartner in China
Topwin pharma
BDM 

Dr. Donghai Chen United States

Protheragen’s business is growing rapidly after founded in Ronkonkoma, New York in 2009. More offices have been established at different locations across China and the US ever since. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.

To continue our development, part of our strategies requires us to constantly seeking high-quality novel drug research and development programs that are open to collaboration opportunities. Relying on strong industry resources and connections built up throughout the years, we welcome partnerships in the following structures: equity investment, intermediary service and project incubation.
Company Size (Fulltime employees)
Please specify your partnering goal
equity investment and program incubation
Headquartner in China
Protheragen Inc.
Business Development Director 

Paul Chen China

Reistone BioPharma is a clinical-stage biotech company focused on developing innovative medicines in autoimmune and autoinflammatory diseases. We are headquartered in Shanghai, China and have offices in Beijing, China as well in Boston and Chicago, US. Our current pipeline includes 4 small molecules in autoimmune and inflammatory diseases where significant gaps exist. The leading asset, a potent selective JAK1 inhibitor, recently completed global Phase II trials in China, US and Europe in atopic dermatitis, ulcerative colitis and Crohn’s disease.

Currently we are looking for either partnership to develop the AD and/or UC or CD indications for Phase III or out-license the global right excluding China market.
Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
Looking to in-license / out-license
Headquartner in China
Biotech/Pharma Asset Stage
Reistone Biopharma
Chief of Staff 
Functionality

Shu Chen

1994年成立上海市国资委直属投资公司
Website:
不对外公开
Partnering Objectives
Headquartner in China
SAIL
投资经理 

Dr. Kai Chen United States

MID Labs has been associated with vitreoretinal surgery from its infancy. Not only has MID Labs invented the tools for modern vitrectomy, but as a company, we have been instrumental in revolutionizing the ophthalmic field through our products.

MID Labs continues to innovate with the MID Labs branded product line which is supplied to more than 30 countries around the world. These products set the standard for precision, performance, and quality.
Website:
midlabs.com
Company Size (Fulltime employees)
Year of foundation
30
Partnering Objectives
Please specify your partnering goal
marketing partner
Headquartner in China
Medtech Category
Medtech Information 1
Vitrectomy cutter||
Medtech Development Stage
MID LABS
CEO 
Functionality

Mr. Shan Chen United States

Late stage venture family office
Website:
www.asset3.com
Company Size (Fulltime employees)
Please specify your partnering goal
Investments
Headquartner in China
CubeTech Holdings
President 
Functionality

Mr. Mark Chen China

Founded in 2009, Kintor Pharmaceuticals concentrates on the R&D and industrialization of “best-in-class” and “first-in-class” innovative drugs and strives to become a leading enterprise in the R&D and commercialization of innovative therapies. On 22 May 2020, Kintor Pharmaceuticals was officially listed on the Hong Kong Stock Exchange with the stock code 9939.HK.
Company Size (Fulltime employees)
Year of foundation
2009
Partnering Objectives
Please specify your partnering goal
Licensing-in
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Kintor Pharmaceuticals
BD Director 
Functionality

Helen Chen

L.E.K. Consulting is a global strategy consulting firm that specializes in corporate strategy, transaction services, and performance improvement. Founded in 1983, we now have more than 1,500 professionals located across major economies worldwide. Clients include Fortune 500, FTSE 100, Eurotop 300, and many of the largest firms in Asia-Pacific.

 

With a reputation for solving the most complex issues, L.E.K. collaborates closely with business leaders and their teams to accelerate the pace and precision of strategic decision-making. L.E.K. works across numerous industry sectors including a strong focus on the healthcare sector.

 

As a leading strategic advisor to the life sciences industry, L.E.K.’s clients include the largest and most advanced pharmaceutical, biotech, medical devices, tools and diagnostics companies. L.E.K.’s global team of life sciences professionals has expertise across all major industry segments and therapeutic areas, and we provide support at each stage of the product life cycle, from drug discovery to commercial optimisation.

 

L.E.K. hosts the Asia Pacific Life Sciences Centre of Excellence in partnership with the Singapore Economic Development Board (“EDB”). This Centre of Excellence (“CoE”) drives thought leadership and innovation to elevate the life sciences ecosystem both in Singapore and across the region.

Website:
www.lek.com
Helen Chen
L.E.K. Consulting
LinkedIn logo Greater China Managing Partner